Um modelo para formação de empresas virtuais no setor de moldes e matrizes

Tese (doutorado) - Universidade Federal de Santa Catarina, Centro Tecnológico. Programa de Pós-Graduação em Engenharia de Produção.O sucesso de uma empresa depende do seu envolvimento em novas oportunidades de negócio. Uma estratégia que as empresas estão utilizando para participar de novos negócios é a de estabelecer relacionamentos diferenciados com clientes, fornecedores e, inclusive, concorrentes. Nos últimos anos, surgiram diferentes formas de cooperação entre empresas devido à forte concorrência e à utilização das modernas Tecnologias de Informação e Comunicação. Entre os modelos emergentes de cooperação entre empresas, o modelo de Empresa Virtual, tem um potencial para ser aplicado por Pequenas e Médias Empresas, trazendo benefícios para as mesmas. No presente trabalho desenvolveu-se um modelo para ser aplicado por Pequenas e Médias Empresas do setor de moldes e matrizes, concorrentes entre si, que tenham a intenção de trabalhar de forma colaborativa formando Empresas Virtuais. No modelo propõe-se que essas empresas, antes de formar Empresas Virtuais, criem um ambiente que lhes permita desenvolver uma nova cultura de trabalho e preparar uma infra-estrutura adequada para sua operacionalização. Esses ambientes foram chamados de Ambientes para Criação de Empresas Virtuais - AmbianCEs. O modelo AmbianCE é constituído por três etapas, quais são: Preparar AmbianCE, Estruturar AmbianCE e Agir, e conta com uma Estratégia, que se baseia na aplicação da Gestão do Conhecimento, para sua implementação. A aplicabilidade do modelo AmbianCE foi verificada em um grupo de empresas concorrentes que atuam no setor de desenvolvimento e fabricação de moldes e matrizes na região de Caxias do Sul, no Estado do Rio Grande do Sul. Pelos resultados obtidos, o modelo proposto mostrou ser eficaz e eficiente, viabilizando a criação de um ambiente favorável para a criação, operação e dissolução de Empresas Virtuais. As empresas que participaram da verificação do modelo AmbianCE cresceram em infra-estrutura, aumentaram o quadro de funcionários, desenvolveram novos clientes e fornecedores e, principalmente, adotaram uma nova forma de trabalho colaborativo

Processos e modos de fabricação de superficies esfericas de precisão

Dissertação (mestrado) - Universidade Federal de Santa Catarina. Centro TecnologicoNo desenvolvimento de mancais aerostáticos necessitam-se calotas esféricas de elevada precisão de forma. o objetivo deste trabalho é o estudo dos diferentes processos e modos de fabricação de superfícies esféricas, considerando os fatores que influenciam a forma e qualidade superficial das mesmas. As condições de usinagem, como a velocidade de corte e avanço, tem influência sobre a forma e a qualidade superficial das superfícies esféricas. Obteve-se menores erros de esfericidade no modo de fresamento, obtendo-se boa repetibilidade dos resultados, na faixa de 4 ± 1mm. A rugosidade Ra obtida foi de 0,68 ± 0,04mm

Influential Factors for Hospital Management Maturity Models in a post-Covid-19 scenario - Systematic Literature Review

The importance of Maturity Models in the health area was proven to support, monitor and direct health organizations to better plan and execute to their investments and developments. In this work, two reviews of the literature were collected: one of them focuses on identifying the main maturity models developed in the health area, the similarities, and gaps between them, identifying which are the Influencing Factors and, the other one, is to identify the lessons learned during the Covid-19 pandemic. In a pandemic scenario, the health sectors demonstrated the importance of the resilience, in which health systems had to adapt abruptly, considering physical structures; professional management; patient safety; supply chain and; technologies. Technologies, played an essential role to mitigating the pressure that health systems faced due to the increase in health costs, growth of chronic diseases, population aging, population’s expectation for more personalized health and, added to that, the confrontation of Covid-19 pandemic. In this sense, we identified the lack of maturity models that address the adversities that occurred during the Covid-19 pandemic in health systems for better hospital management and avoid the pressure to which they could be subjected again.info:eu-repo/semantics/publishedVersio

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

¡Con la Razón y la Fuerza, Venceremos!

Cuando a comienzos de septiembre de 1980 Luis Corvalán, Secretario General del Partido Comunista de Chile, hizo anuncio del derecho a la rebelión y al empleo de todas las formas de lucha para enfrentar a la Dictadura de Pinochet, se abrió una nueva fase en la política partidaria y nacional. Desde entonces, los documentos y comunicaciones públicas comunistas -y, por cierto, su práctica- comenzaron a definirse en torno a la consigna que sintetizaba la nueva disposición combatiente: ¡Con la razón y la fuerza, venceremos! ¿Qué significaba esta posición? ¿Hasta qué punto difería o no de la “política de masas” tradicional del PC? ¿Qué factores subjetivos y del ánimo militante jugaron a favor de su puesta en marcha? ¿Qué tensiones y conflictos generó al interior de su aparato dirigente? ¿Qué tipo de consecuencias e implicancias traería el llamado a la rebelión popular de masas? ¿Fue el FPMR el resultado lógico y necesario del cambio en la orientación? Premunido de un adecuado manejo de fuentes y antecedentes, varios de ellos escasamente conocidos hasta hoy, este libro de la joven investigadora Viviana Bravo Vargas nos sitúa en el contexto político y partidario de la época, hace hablar a numerosos protagonistas y nos sugiere diversos enfoques y repuestas en torno a la formulación y suerte de la Política de Rebelión de Masas que enarboló el comunismo nacional en los dramáticos años de la lucha antifascista

Collective Competence and Social Capital Analysis in Collaborative Networks

The present paper addresses the issue of collective competence and social capital analysis for collaborative networks. The objective of the project is to understand how collaborative networks can be influenced considering the perspective of social capital and core competences. In this model we defend the emphasis on endogenous resources, once the technology is, in a general way, accessible to most of the companies and, therefore will not be a long term competitive advantage. The model shows that collaborative networks will be more competitive and successful if they invest in to core elements that are: organizational culture and people. Therefore, the model contributes for the researches in socio-organizational filed and provides a tool to evaluate collaborative networks

Un trébol de cuatro hojas

No obstante la actualización experimentada por la historiografía política chilena reciente, entre los aspectos que aún han sido débilmente abordados se encuentran aquellos vinculados a sus estructuras juveniles. Este libro compila trazos generales y fragmentarios sobre la historia de la JJCC a lo largo del siglo XX, desde sus acciones organizativas primigenias en el norte salitrero; sus diversos avatares constitutivos luego de la dictadura de Ibáñez; su rol en los procesos de politización juvenil durante los años del Frente Popular; algunos acercamientos a la cultura juvenil comunista en los años 60 y 70; y ciertos elementos sobresalientes de la actuación jotosa en el terreno de las luchas estudiantiles en los tiempos de la Reforma Universitaria, bajo la Dictadura y durante los gobiernos de la Concertación. Tratándose de una historia que no quiere perdurar sino prosperar, al final se incluyen algunos relatos testimoniales de jotosos que han permanecido en la organización (ahora, en calidad de militantes del partido) o que lo fueron, habiendo salido luego de ella.A los jóvenes comunistas de siempre A los conocidos y a los ignorados A los que se empeñaron A los que padecieron A los que pasaron A los abandonados A los que vuelven cada dí

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus.METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-analysis.RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (&lt;45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]).CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02065791